Flok Health Closes $12.5M to Expand AI Physiotherapy

The big picture: Flok Health, an AI-operated digital care platform, has closed $12.5 million in an oversubscribed Series A funding round led by Albion VC, with participation from existing investors Eka VC and Form Ventures, as well as new investor Mercia Ventures. The funding will support the expansion of Flok’s AI-operated physiotherapy services across the UK, the development of new clinical pathways, and entry into international markets.

Why it matters:

• Addressing demand: Healthcare providers face growing demand for musculoskeletal (MSK) services, while limited clinical capacity and long waiting lists create challenges for timely access to care.
• NHS impact: Flok’s platform is currently available to over 2.4 million NHS patients across eleven regions in the UK, providing on-demand back pain treatment without waiting lists.
• Patient satisfaction: During a recent NHS rollout, more than 80 percent of patients reported that the AI clinic was as good as or better than traditional in-person physiotherapy, while generating significant clinical time savings.

How it works:

• AI consultation: Flok Health has developed an AI-operated digital physiotherapy clinic delivered through a mobile application that simulates a live consultation experience using real footage of a physiotherapist and responds in real-time to patient inputs.
• Autonomous care: The company states its platform is capable of autonomously delivering complete physiotherapy care pathways without clinician oversight.
• Certified medical device: Flok is approved as a healthcare provider by the UK’s Care Quality Commission and holds Class IIa medical device certification for the autonomous delivery of full care pathways.

The catch: While Flok Health’s AI-operated platform has achieved medical device certification and demonstrated efficacy in NHS deployments, the broader adoption of fully autonomous AI in healthcare may still face public trust hurdles. Expanding into new clinical pathways like hip and knee pain and women’s pelvic health, and entering international markets, will require continuous rigorous validation and adaptation to diverse regulatory landscapes and patient expectations.